Barclays Keeps Their Hold Rating on Apellis Pharmaceuticals (APLS)

In a report released today, Eliana Merle from Barclays maintained a Hold rating on Apellis Pharmaceuticals, with a price target of $24.00.

Claim 50% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Merle covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, BridgeBio Pharma, and Alnylam Pharma. According to TipRanks, Merle has an average return of 4.4% and a 43.78% success rate on recommended stocks.

In addition to Barclays, Apellis Pharmaceuticals also received a Hold from TipRanks – Google’s Google Biotechnology in a report issued today. However, yesterday, Bank of America Securities reiterated a Buy rating on Apellis Pharmaceuticals (NASDAQ: APLS).

Based on Apellis Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $458.58 million and a net profit of $215.72 million. In comparison, last year the company earned a revenue of $196.83 million and had a GAAP net loss of $57.45 million

Based on the recent corporate insider activity of 79 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of APLS in relation to earlier this year. Earlier this month, Mark Jeffrey DeLong, the Chief Business & Strat Officer of APLS sold 368.00 shares for a total of $8,151.20.